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Triangulating evidence 
from longitudinal and Mendelian 
randomization studies 
of metabolomic biomarkers 
for type 2 diabetes
Eleonora Porcu1,2,10*, Federica Gilardi3,4,10, Liza Darrous2,5, Loic Yengo6, Nasim Bararpour3,4, 
Marie Gasser3,4, Pedro Marques‑Vidal7, Philippe Froguel8,9, Gerard Waeber7, 
Aurelien Thomas3,4,11 & Zoltán Kutalik2,5,11* 
The number of people affected by Type 2 diabetes mellitus (T2DM) is close to half a billion and is on a 
sharp rise, representing a major and growing public health burden. Given its mild initial symptoms, 
T2DM is often diagnosed several years after its onset, leaving half of diabetic individuals undiagnosed. 
While several classical clinical and genetic biomarkers have been identified, improving early 
diagnosis by exploring other kinds of omics data remains crucial. In this study, we have combined 
longitudinal data from two population‑based cohorts CoLaus and DESIR (comprising in total 493 
incident cases vs. 1360 controls) to identify new or confirm previously implicated metabolomic 
biomarkers predicting T2DM incidence more than 5 years ahead of clinical diagnosis. Our longitudinal 
data have shown robust evidence for valine, leucine, carnitine and glutamic acid being predictive of 
future conversion to T2DM. We confirmed the causality of such association for leucine by 2‑sample 
Mendelian randomisation (MR) based on independent data. Our MR approach further identified 
new metabolites potentially playing a causal role on T2D, including betaine, lysine and mannose. 
Interestingly, for valine and leucine a strong reverse causal effect was detected, indicating that the 
genetic predisposition to T2DM may trigger early changes of these metabolites, which appear well‑
before any clinical symptoms. In addition, our study revealed a reverse causal effect of metabolites 
such as glutamic acid and alanine. Collectively, these findings indicate that molecular traits linked to 
the genetic basis of T2DM may be particularly promising early biomarkers.
Type 2 Diabetes Mellitus (T2DM) is a major public health concern and its prevalence is increasing. Almost 500 
million individuals are currently affected worldwide by diabetes and almost 700 million may be affected by 2045 
[https ://www.diabe tesat las.org/en/secti ons/world wide-toll-of-diabe tes.html]. Diabetes remains among the lead-
ing causes of cardiovascular disease, blindness, kidney failure, and lower-limb amputation. By the time T2DM is 
diagnosed, many individuals have already established end-organ damage including neuropathy, kidney failure 
and/or premature cardiac or brain atherosclerosis. Diabetes and pre-diabetes are diagnosed by routinely assessed 
clinical markers [glycaemia and glycated haemoglobin  (HbA1c) levels] above a given threshold. Still, agreement 
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between the different markers in diagnosing T2DM is not  optimal1, and their screening capacity for pre-diabetes 
is  low2. While these markers are powerful predictors of the disease, they are far from perfect for the identification 
of individuals who are prone to develop T2DM. Early detection of individuals with high T2DM predisposition is 
important as non-pharmacological approaches (i.e. lifestyle changes) can reduce substantially (and at a reduced 
cost) the risk of developing  T2DM3,4. Several predictive scores have been developed using clinical and genetic 
data (e.g.5,7.), but their performance is far from optimal. Since many metabolites and proteins are expected to 
be altered in pre-diabetic state, using different omics profiles in addition to the classical clinical, biological and 
genetic risk factors is expected to increase the prediction accuracy.
Several cross-sectional and longitudinal metabolomic studies, focussing on blood samples using targeted 
approaches, have been initiated to identify candidate biomarkers of pre-diabetes, with a few exceptions employ-
ing untargeted approaches (e.g. a cross-sectional study of 115 T2DM  individuals8). In the population-based 
cooperative health research of Augsburg (KORA), 140 metabolites were quantified for 4297 participants and 
several metabolites altered in pre-diabetic individuals have been  identified9. Using metabolite-protein network 
and targeted approaches on serum samples, Wang-Sattler et al. identified seven T2DM-related genes associated 
with these metabolites by multiple interactions with four enzymes. Lysophosphatidylcholine (18:2) and glycine 
were strong predictors of glucose intolerance, even 7 years before disease onset. These metabolites, in addition to 
sugar metabolites, acylcarnitines and other aminoacids, have been identified as predictors of T2DM also in the 
European Prospective Investigation into Cancer and nutrition  cohort10. More recently, Padberg et al. described 
a metabolic signature that includes glyoxylate associated with T2DM and prediabetic  individuals11. Wang et al. 
using longitudinal data on 201 incident T2DM cases, identified a signature of five branched-chain and aromatic 
metabolites for which individuals in the top quartile exhibited a five-fold higher risk to develop  T2DM12. Par-
ticularly, a combination of three amino acids predicted future T2DM, with a more than five-fold higher risk 
for individuals in top quartile, suggesting that amino acid profiles could aid in diabetes risk assessment. These 
results were confirmed by a recent meta-analysis from 8 prospective studies on 8000 individuals, which found 
a higher risk of T2DM for isoleucine, leucine, valine and  phenylalanine13.
By targeting serum carnitine metabolites on 173 incident T2DM cases among 2519 patients with coronary 
artery disease, Strand et al. demonstrated that trimethyl-lysine, g-butyrobetaine, as both precursors on free 
carnitine and palmitoyl-carnitine, predict long-term risk of T2DM independently of traditional risk  factors14.
As another example, shotgun lipidomics was applied in a transversal study on plasma of pre-diabetic mice 
from different genetic backgrounds and revealed a group of ceramides correlated with glucose tolerance and 
insulin  secretion15. These results were interestingly confirmed by quantitative analysis in the plasma of individu-
als from two population-based prospective cohorts showing that dihydro-ceramides were significantly elevated 
in the plasma of individuals who will progress to diabetes up to 9 years before disease  onset15. Other studies 
have struggled to identify the contribution of individual metabolites and focused more on metabolome-wide 
 prediction16, which are difficult to replicate.
The previously listed studies provide several important candidate metabolites to benchmark our experimental 
and modelling setup. Here, we used a subset of the CoLaus study intentionally enriched for T2DM incident cases 
to maximise discovery power of baseline metabolite levels being associated with developing T2DM at a later 
follow-up stage. We compared our findings with a similarly sized population-based cohort, DESIR, and also with 
bidirectional Mendelian randomisation using metabolite- and T2DM QTLs as instruments.
Methods
The CoLaus study. The CoLaus study (www.CoLau s-psyco laus.ch) is a population-based prospective study 
based on a single random sample of 6733 participants from the overall population aged between 35 and 75 living 
in Lausanne (10). The baseline survey was conducted between 2003 and 2006. Each participant was extensively 
phenotyped regarding personal, lifestyle and cardiovascular risk factors; extensive blood and urine characteriza-
tion was performed, and over 500,000 SNPs were directly genotyped and a further 20.4 million imputed (with 
r2-hat > 0.3). The first follow-up was performed between April 2009 and September 2012; median follow-up time 
was 5.4 (average 5.6, range 4.5–8.8) years; it included 5064 participants, and the 5.5-year incidence of T2DM was 
6.5%, with 284 incident cases. The second follow-up was performed between May 2014 and April 2017; median 
follow-up was 10.7 (average 10.9, range 8.8–13.6) years. In this study, we selected 262 T2DM incident cases at 
the first follow-up and 524 controls matched for sex, age and baseline glucose. For each case, two types of con-
trols were selected: one with a very low risk of T2DM (as assessed by a multivariable T2DM risk  score17) and 
one with pre-diabetes (with a high-risk score, but no T2DM at the CoLaus second follow-up) (Fig. 1). Incident 
T2DM cases were defined as fasting glucose ≥ 7 mmol/L and/or presence of antidiabetic drug treatment and/or 
HbA1c ≥ 6.5%. The most important study characteristics are included in Table 1. All research was performed in 
accordance with relevant guidelines and regulations. The study protocols were approved by the Ethical Commit-
tee of the Canton de Vaud and all participants provided written informed consent.
The DESIR cohort. The prospective D.E.S.I.R. cohort is a 9-year follow up study of 2391 middle-aged Euro-
pean ancestry  participants18–20. We analysed participants from a case-cohort design embedded within the larger 
cohort that includes 231 cases of incident T2DM and 836 participants randomly sampled from the entire cohort. 
Baseline and follow-up clinical characteristics of participants included in the training population are shown 
 in5 (see Table 1). T2DM was defined using one of the following criteria: use of glucose lowering medication, 
fasting plasma glucose [FG] ≥ 7 mmol/L, or glycated hemoglobin A1c  [HbA1c] ≥ 6.5% (48 mmol/mol). Clinical 
and biological evaluations were performed at inclusion and after 3, 6, and 9 years, as previously  described21. 
All research was performed in accordance with relevant guidelines and regulations. All participants provided 
written informed consent and the study protocol was approved by the Ethics Committee for the Protection of 
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Figure 1.  Flowchart of participant selection from CoLaus study.
Table 1.  Sample characteristics of the CoLaus and DESIR studies. Yn denotes n years after baseline (e.g. Y3 
means a follow-up 3 years after baseline). N stands for sample size. Values are either number (% of total), 
median [interquartile range] or mean ± standard deviation.
CoLaus DESIR
Y0 Y5 Y10 Y0 Y3 Y6 Y9
N 788 788 673 984 961 932 957
Gender 
(woman) 268 (34.0) 268 (34.0) 240 (35.7) 469 (47.7) 455 (47.3) 442 (47.4) 462 (48.3)
Age (years) 56.2 ± 9.7 61.8 ± 9.7 66.7 ± 9.5 48.2 ± 10.1 51.2 ± 10.1 54.2 ± 10.1 57.2 ± 10.1
Smoking categories (%)
 Never 283 (35.9) 280 (36.0) 237 (38.4) 484 (49.2) 474 (49.3) 456 (48.9) 473 (49.4)
Former 302 (38.3) 339 (43.6) 284 (46.0) 278 (28.3) 272 (28.3) 264 (28.3) 270 (28.2)












index (kg/m2) 27.1 ± 4.6 27.5 ± 4.9 27.8 ± 5.1 25.1 ± 4.0 25.6 ± 4.4 26.0 ± 4.5 26.2 ± 4.5
Waist (cm) 94.2 ± 13.1 97.1 ± 13.2 97.7 ± 13.9 84.5 ± 12.1 85.9 ± 12.6 87.5 ± 12.9 88.2 ± 13.1
HDL (mmol/L) 1.53 ± 0.42 1.53 ± 0.44 1.49 ± 0.46 1.61 ± 0.42 1.51 ± 0.39 1.62 ± 0.40 1.47 ± 0.34
Triglycerides 
(mmol/L) 1.3 [0.9–1.9] 1.3 [0.9–1.8] 1.2 [0.9–1.7] 1.2 [0.7—1.5] 1.3 [0.7—1.6] 1.3 [0.8—1.6] 1.3 [0.8—1.5]
Glucose 
(mmol/L) 5.68 ± 0.66 6.38 ± 1.13 5.98 ± 1.39 5.39 ± 0.57 5.53 ± 0.84 5.63 ± 1.04 5.67 ± 1.06
Insulin (μU/
mL) 8.2 [5.1–12.4] 8.3 [5.2–13.5] 9.8 [5.9–14.8] 7.1 [4.2—8.3] 7.0 [4.2—8.4] 7.5 [3.9—9.0] 7.3 [4.1—8.7]
HOMA2-IR 2.1 [1.3–3.3] 2.4 [1.4–4.0] 2.6 [1.4–4.2] 1.1 [0.7—1.3] 1.1 [0.7—1.3] 1.2 [0.7—1.5] 1.2 [0.7—1.4]
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Subjects for Biomedical Research of Bicêtre Hospital, France. Metabolites measurements have been described 
elsewhere in full  details21.
Targeted metabolomics analysis. Plasma and urine samples collected at the baseline of the CoLaus 
cohort were processed for targeted metabolomics analysis as described  elsewhere22. Briefly, metabolites were 
extracted from 100 µL of plasma or urine samples and Quality Control (QC) samples using a cold methanol-
ethanol solvent mixture in a 1:1 ratio. After centrifugation at 14,000 rpm for 15 min, supernatant was recovered, 
evaporated and resuspended in 100 µL (for plasma) or 200 µL (for urine) of  H2O:MeOH (9:1). 5 µL of the sam-
ples were analyzed by LC-MRM/MS on a hybrid triple quadrupole-linear ion trap  QqQLIT (Qtrap 5500, Sciex) 
hyphenated to a LC Dionex Ultimate 3000 (Dionex, Thermo Scientific). Analyses were performed in positive 
and negative electrospray ionization using a TurboV ion source. The chromatographic separation was performed 
on a Kinetex column C18 (100 × 2.1 mm, 2.6 µm). The mobile phases were constituted by A:  H2O with 0.1% FA 
and B: ACN with 0.1% FA for the positive mode. In the negative mode, the mobile phases were constituted by A: 
ammonium fluoride 0.5 mM in  H2O and B: ammonium fluoride 0.5 mM in ACN. The linear gradient program 
was 0–1.5 min 2%B, 1.5–15 min up to 98%B, 15–17 min held at 98% B, 17.5 min down to 2%B at a flow rate of 
250 µL/min.
The MRM/MS method included 299 and 284 transitions in positive and negative mode respectively, cor-
responding to 583 endogenous metabolites. For each biological matrix, the 786 samples were prepared and 
analyzed in 8 batches. In order to monitor the signal drift and system performance over time, and to avoid 
repeated thawing-freezing cycles of the study samples, quality control (QCs) surrogate samples were used. These 
QC samples were prepared in the same way and at the same time of the study samples from aliquots of a pool 
of human plasma or urine that was the same for all the analytical batches. QC samples were injected every 8 
samples in both positive and negative modes.
The MS instrument was controlled by Analyst software v.1.6.2 (AB Sciex). Peak integration was performed 
with MultiQuant software v.3.0 (AB Sciex). The integration algorithm was MQ4 with a Gaussian smoothing of a 
half-width equal to 1.5 points. For plasma samples, the analysis was narrowed to the 124 and 48 metabolites that 
were detected in all samples with a noise percentage of 80% and a gaussian peak shape, in positive and negative 
modes, respectively. For urine samples, we detected 124 and 77 metabolites in positive and negative modes, 
respectively. In case of remaining missing values, they were replaced by the lowest value of the corresponding 
metabolite. To correct for batch effect, raw data were normalized with the dbnorm  package23, by using the ber 
model.
Statistical approaches. We performed logistic- and linear regression analysis to test for association 
between baseline metabolite levels and T2DM incidence and glucose level changes, respectively. We included 
the following covariates: family history of diabetes, smoking status, body-mass index (BMI), HDL cholesterol, 
triglycerides, insulin, glucose and HOMA measure at baseline. Since none of our association P values passed 
strict Bonferroni correction for multiple testing (P < 0.05/172) or FDR correction (PFDRadj < 0.05), we declared P 
values below 0.01 as suggestively significant.
Bi‑directional metabolome‑wide mendelian randomization. To explore the causal paths between 
metabolites and glucose and T2DM, we performed Mendelian randomization (MR), an instrumental variable 
method to distinguish correlation from causation in observational  data24. The idea of MR is to use genetic vari-
ants as instrumental variables to attempt causal inference about the effect of modifiable risk factors, which can 
overcome some types of confounding and reverse causation.
We performed two-sample bidirectional MR. We tested whether genetically varying levels of a particular 
metabolite affect the risk for elevated glucose and T2DM (we call this MR) and whether genetically increased risk 
of T2DM or elevated glucose is associated with circulating levels of a particular metabolite (we call this reverse 
MR). The associations between the instrumental variables and the exposure and the outcome are estimated from 
independent studies.
To run MR for each metabolite, as instrumental variables, we used independent (pairwise  r2 < 0.01) significant 
(P < 1 ×  10–05) SNPs associated with the metabolite in study (Supplementary Table 1). Such data are from a large 
GWAS performed for 453 whole blood metabolites in 7824 European  individuals25. To run the reverse MR, for 
glucose and diabetes we used as instrumental variables the independent  (r2 < 0.01) genome-wide significant 
SNPs (P < 5 ×  10–08) found by the GWASs performed on UKBB and the DIAGRAM Consortium for  T2DM26, 
respectively (Supplementary Table 2).
Results
Study characteristics. Selected basic features of the CoLaus study are listed in Table 1. We selected 788 
participants, including 263 T2DM incident cases at the first follow-up and 525 controls matched for sex, age and 
baseline glucose. Summary data are expressed either as counts (and percentage) for categorical variables and as 
median [interquartile range] or mean ± standard deviation for continuous variables.
Metabolites association scan. Based on quality criteria such as sensitivity and peak shape, we detected 
172 urine and plasma metabolites (MS) in the 788 selected CoLaus participants. The analytical samples were 
collected at the baseline and included 525 participants without diabetes and 263 participants who became dia-
betic over the following 10 years. For each metabolite, we ran logistic/linear regression analysis with diabetes 
incidence/change in glucose levels as outcome and family history of diabetes, smoking status, body-mass index 
(BMI), HDL cholesterol, triglycerides, insulin, glucose and HOMA measure at baseline, metabolite levels as 
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independent variables. Note that we tested only one metabolite at a time and ran a separate model for each 
metabolite.
Here, all the results are based on the first CoLaus follow-up which is the best powered for predictive analysis. 
Indeed, when we compared the effects estimated in the first and second follow-up we observed significant weaker 
effects in the second follow-up (Pt-test = 1.38 ×  10–05, see Fig. 2). It is logical that as more time passes, other factors 
emerge that may influence diabetes incidence, reducing the predictive power of baseline biomarkers.
The metabolome-wide association scan revealed seven metabolites associated with glucose change at sug-
gestively significant level (P < 0.01) in the CoLaus study, see Table 2. When we meta-analysed metabolome-wide 
results from the CoLaus and DESIR studies, we similarly found leucine and four additional suggestively signifi-
cant (P < 0.01) metabolites associated with glucose change (Table 3). As DESIR is a 9-year follow up study where 
biological evaluations were performed every 3 years, we used the data collected in the second follow-up (after 
6 years) to match as closely as possible the 5-years follow-up performed in CoLaus.
Metabolome‑wide mendelian randomization. Table 4 shows the significant results from the metabo-
lome-wide MR approach. Among the 453 testable metabolites, genetically altered levels of one and six metabo-
lites were found significantly associated with glucose and T2DM, respectively. These include betaine, mannose, 
lysine, and three phospholipid species.
Applying the reverse MR, we found that the genetic predisposition to T2DM is associated with the levels of 
12 metabolites.
Figure 2.  Linear relationship between the effects estimated in the first (F1) and second (F2) follow-up. The blue 
and grey lines represent the regression and the identity line respectively.
Table 2.  Metabolites associated with glucose change in the CoLaus cohort. For each metabolite we report its 
effect size on glucose in the CoLaus and DESIR cohorts, the combined P value and the forward and reverse 
causal effect on glucose and T2DM estimated by Mendelian Randomisation. “X” indicates missing value, i.e. 
when the metabolite was not available for the respective analysis. The ID for the Human Metabolome Database 
is indicated for each metabolite.
Metabolite









Effect P value Effect P value P value Effect P value Effect P value Effect P value Effect P value
Valine (HMDB0000883) 0.095 9.00E−04 0.005 0.853 0.069 0.000 1.000 0.104 0.023 0.023 0.008 0.115 0.003
Leucine (HMDB0000687) 0.088 0.0021 0.046 0.158 2.90E−03 0.002 0.372 0.042 0.360 0.007 0.011 0.159 5.79E−05
Sarcosine (HMDB0000271) 0.081 0.0039 0.014 0.581 0.076 x x x x x x x x
4-Hydroxyproline 
(HMDB0006055) 0.083 0.0042 − 0.039 0.116 0.94 x x x x x x x x
Glutamic acid (HMDB00148) 0.074 0.009 − 0.038 0.185 0.656 0.01 0.147 0.069 0.134 0.012 0.12 0.18 2.84E−06
Homoserine (HMDB0000719) 0.078 0.0094 x x x x x x x x x x x
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None of the metabolites found significant by MR was associated with glucose in CoLaus (P > 0.05). By con-
trast, among the seven metabolites reported in Tables 2 and 3, three were testable with MR. While we did not 
observe any significant effect for glucose, T2DM showed a significant causal effect on valine (P = 0.003), leucine 
(P = 5.8 ×  10–05) and glutamate (P = 2.8 ×  10–06).
Discussion
Using mass-spectrometry targeted metabolomics analysis, we identified a panel of metabolites whose levels are 
associated with glucose changes before the onset of T2DM in the CoLaus Cohort. We replicated our findings in 
an independent study (DESIR), which reassuringly revealed five metabolites with combined P value below 0.01, 
including l-carnitine, leucine, and cortisol. In addition, we applied a metabolome-wide Mendelian Randomi-
zation (MR) approach which allowed us to confirm the causal effect of leucine on T2DM, but also to identify 
Table 3.  Additional metabolites found significantly associated with glucose change after combining CoLaus 
and DESIR Cohort results. For each metabolite we report its effect size on glucose in CoLaus and DESIR 
cohorts, the combined P value and the forward and reverse causal effect on glucose and T2DM estimated by 
Mendelian Randomisation. The ID for the Human Metabolome Database is indicated for each metabolite.
Metabolite









Effect P value Effect P value P value Effect P value Effect P value Effect P value Effect P value
L-carnitine (HMDB00062) 0.046 0.111 0.091 3.26E−04 8.30E−05 0.00 0.358 0.05 0.314 0.00 0.199 0.09 0.027
Leucine (HMDB0000687) 0.088 0.002 0.046 0.158 0.003 0.00 0.372 0.04 0.360 0.01 0.011 0.23 5.81E−07
Phenylacetylglutamine 
(HMDB0006344) − 0.040 0.204 − 0.058 0.013 0.006 − 0.001 0.429 0.037 0.415 − 0.01 0.2 0.008 0.836
Pantothenic acid 
(HMDB00210) 0.047 0.114 0.065 0.026 0.007 x x x x x x x x
Cortisol (HMDB00063) − 0.049 0.061 − 0.046 0.059 0.009 − 0.01 0.116 − 0.02 0.669 − 0.01 0.198 − 0.07 0.086
Table 4.  Metabolome-wide mendelian randomization results. The ID for the human metabolome database is 






Metabolite → Glucose Betaine (HMDB0000043) − 0.022 0.005 4.89E−05
Metabolite → T2DM
Mannose (HMDB0000169) 0.052 0.007 9.06E−15
Lysine (HMDB0000182) 0.047 0.009 5.43E−08
X-02249* − 0.033 0.008 3.98E−05
LysoPE(18:2(9Z,12Z)/0:0) (HMDB0011507) − 0.042 0.008 1.78E−07
LysoPC(14:0/0:0) (HMDB0010379) − 0.048 0.012 3.52E−05
LysoPE(18:1(9Z)/0:0) (HMDB0011506) − 0.050 0.011 1.63E−06
Glucose → Metabolite
Fructose (HMDB0000660) 0.257 0.065 6.60E−05
Mannose (HMDB0000169) 0.404 0.065 5.26E−10
Glucose (HMDB0000122) 0.698 0.065 9.29E−27
Hyodeoxycholic acid (HMDB0000733) 0.280 0.066 2.35E−05
T2DM → metabolite
Leucine (HMDB0000687) 0.232 0.046 5.81E−07
2-hydroxypropanoic acid (HMDB0144295) 0.186 0.046 5.79E−05
Fructose (HMDB0000660) 0.194 0.045 1.54E−05
Mannose (HMDB0000169) 0.436 0.049 7.68E−19
Proline (HMDB0000162) 0.190 0.045 2.73E−05
Glucose (HMDB0000122) 0.380 0.047 4.29E−16
Glutamic acid (HMDB0000148) 0.213 0.045 2.28E−06
Alanine (HMDB0000161) 0.191 0.046 3.38E−05
X-11317* − 0.183 0.046 7.98E−05
X-12696* − 0.185 0.045 4.79E−05
X-12844* 0.180 0.045 6.63E−05
X-14625* 0.232 0.045 3.26E−07
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new reverse causal relationships between glucose/T2DM and metabolites, such as leucine, valine, glutamic acid, 
alanine and mannose.
While we focused our analysis on predicting T2DM for a 5-years follow-up period, we observed that the 
effect of the potentially predictive metabolites diminished over time. This is unsurprising as risk factors change 
over time, hence more and more unknowns contributing to diabetes conversion accumulate with time. We have 
noticed, furthermore, that more than 80% (140/172) of the metabolite effects are positive, meaning that generally 
an increased level of metabolites represents a risk factor for diabetes. This observation needs to be considered 
with caution, since it might be due to a latent diabetes-associated confounding factor, which is linked to overall 
metabolite concentration. This explanation is rather unlikely since we accounted for metabolomic principal 
components in all association scan.
The confirmed metabolites have been repeatedly supported by various types of evidence in both human 
and model organisms. Individuals with obesity and T2DM have elevated levels of branched-chain amino acids 
(leucine, isoleucine and valine)12,27–30. Such changes are already present before the onset of  diabetes12,13,31,32 and 
their causal role is believed to be exerted via the modulation of the mTOR pathway. Increased leucine levels 
can lead to insulin resistance via activation of the TORC1 pathway, with induction of beta cell proliferation and 
insulin  secretion12,33 and disruption of insulin signal in skeletal  muscle34. On the other hand, insulin resistance 
enhances protein catabolism in skeletal muscle, which can increase the release of branched-chain amino  acids35. 
Moreover, hyperglycemia negatively correlates with adipose tissue expression of genes involved in branched-chain 
amino acid oxidation, which can further contribute to raise the levels of BCAA 35. Thus, so far it remains unclear 
whether the observed BCAA changes are only a consequence of hyperglycemia or if they have a causative role 
in the development of T2DM.
Another metabolite which is displaying a significant association with glucose changes in the CoLaus cohort 
is glutamic acid, although this is not replicated in the DESIR study. A link between increased glutamate levels 
and insulin resistance traits was already observed in multiple  cohorts28,32,36, and more recently, a meta-analysis 
conducted in 18 prospective studies highlighted glutamate as positively correlated with  T2DM37. Glutamate is a 
glucogenic aminoacid, which can enter into the Krebs cycle through its conversion to α-ketoglutarate. In addi-
tion, it can favour gluconeogenesis by increasing the transamination of pyruvate to  alanine38, and can directly 
stimulate glucagon release from pancreatic α-cells39. However, its possible causal role remains controversial and 
several reports suggest that it is rather a reduced ratio between glutamine, a glutamate derivative, and glutamate 
itself, that is informative of metabolic  risk36,40.
In our study, free carnitine, cortisol, phenylacetylglutamine and pantothenic acid also appeared as significantly 
associated to the development of T2DM, although only when our data were combined with the French cohort 
(CoLaus + DESIR). Carnitine esterification with fatty acids is required for the shuttling of the latter into the 
mitochondria for fatty acid oxidation. Lower levels of free carnitine were reported in diabetic  individuals14,41,42, 
while changes of acylcarnitines and/or carnitine precursors were highlighted in several studies as indicators of 
prediabetes/T2DM9,10,29, although data are not always consistent. Our targeted LC–MS method included several 
of these acylcarnitines, such as acetylcarnitine, propionylcarnitine, and isovalerylcarnitine, but no significant 
association was found with subsequent development of T2DM.
Cortisol dysregulation has been linked to T2DM in cross-sectional and longitudinal  studies43,44. More specifi-
cally, diabetic individuals present a flattened diurnal cortisol curve compared to non-diabetic  ones45, with lower 
morning and higher afternoon and evening  concentrations46. Interestingly, high levels of evening cortisol were 
also shown to be predictive of T2DM development in an occupational  cohort47. Even though the mechanisms 
underlying this association are not completely understood, cortisol contributes to many metabolic processes 
that can potentially perturb glucose  homeostasis48. Cortisol has a major role in raising glucose levels through 
gluconeogenesis activation. Moreover, it induces lipolysis, thus increasing the release of free fatty acids that may 
favour the impairment of glucose uptake. Of note, diabetes is considered a common complication in clinical 
states characterized by prolonged hypercortisolaemia, such as in Cushing  disease49. However, the causality of 
this association remains to be determined. Phenylacetylglutamine is a nitrogenous metabolite almost exclusively 
derived from the gut microbiota conversion of  phenylalanine50. Its accumulation is known to occur in uraemia 
and was shown to be increased in type 2 diabetic patients, particularly in association with renal  damage51,52. 
Other findings with variable degree of evidence in our study have also solid corroborating literature. Sarcosine 
(N-methylglycine) is an intermediate and by-product in glycine synthesis and has been found to be a moderately 
strong (OR = 1.3) predictor of T2DM  incidence53. More specifically, the addition of urine sarcosine to other 
established predictors of incident T2DM was shown to improve model performance and T2DM risk prediction 
in a cohort of 4164 patients with suspected stable angina pectoris. Diabetic individuals have higher circulating 
proline levels and, moreover, proline-induced insulin transcription impairment may contribute to the β-cell 
dysfunction observed in  T2DM54.
Causal inference. Drawing causal inference is extremely difficult. While most human studies are observa-
tional and cross-sectional predominantly, only correlations are calculated between a disease status and the levels 
of various predictors. Such a simple measure cannot tease apart forward-, reverse causation or confounding. 
Longitudinal studies provide more specific directional link (called Granger causality) between a potential bio-
marker and disease outcomes. With its roots in differential equation modelling, an association between the base-
line level of a predictor and the change of the outcome over time may imply a causal relationship. An orthogonal 
axis of evidence for causality can be provided by Mendelian randomization (MR), where exposure-associated 
genetic markers act as instruments to tease out the causal relationship between a potential risk factor and an 
 outcome24. Interventional studies, due to their intrusive nature are performed mostly in model organisms and 
can help triangulating causal evidence. Comparisons between the different approaches for causality have been 
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very scarce due to the little overlap between the respective scientific communities. A pioneering  work55 in this 
aspect has shown good agreement between disease-to-biomarker MR results, observational correlation and lon-
gitudinal associations. However, their longitudinal association included exposure (adiposity) change regressed 
on outcome (metabolite level) change, which implies no directionality and is not the intuitive way to perform 
such analysis.
Several MR studies have explored the causal effect of possible metabolite markers on T2DM. However, they 
mainly focused on classic blood lipid  markers56–58 and on aminoacids previously associated to T2DM, such as 
 BCAAs4,59,60. Among the previously investigated metabolites we could test only 12 (2-methylbutyroylcarnitine, 
alanine, bilirubin, citrulline, glutamate, isoleucine, leucine, N-acetylglycine, phenylalanine, tryptophan, tyrosine 
and valine). Apart from replicating the association of leucine and valine, we have shown that leucine has bidi-
rectional causal relationship with diabetes, with a larger reverse (diabetes to leucine) causal effect. Our finding 
is consistent with a previous report that suggested that insulin resistance might drive higher levels of circulating 
 BCAAs56. Moreover, in our study, (predisposition to) diabetes has a significant causal effect also on glutamate and 
valine, while their direct effect on diabetes is not significant. Hence small molecules targeting these metabolites 
may be more effective for treating downstream organ damage of T2DM, such as cardiovascular disease, neuropa-
thies or nephropathy. In line with this hypothesis, glutamate accumulation in the retina can cause neurotoxicity 
and the development of diabetic  retinopathy61,62, even though the actual connection between plasma and retinal 
glutamate levels remains to be  assessed40.
Interestingly, our metabolome-wide MR approach further highlighted new causal relationships between 
additional metabolites and glucose/T2DM. Betaine, for instance, which was previously found to have a protec-
tive role in  T2DM53, appears to have a causal effect on glucose. Alterations of lysine levels were also already 
associated to T2DM  risk63. Another interesting metabolite, which shows bidirectional causal effect on T2DM 
in our study, is mannose, a hexose with essential function for glycoprotein synthesis. Mannose was repeatedly 
found as associated with high glucose levels and with the development of T2DM in prospective  studies8,10,64,65. 
Of note, this carbohydrate might be directly synthesized from  glucose66, which could explain the causal effect 
of glucose itself and of T2DM on mannose levels, while the understanding of the opposite effect (metabolite 
on T2DM onset) requires more investigations. Finally, we found a significant causal effect of T2DM on alanine 
levels, in agreement with a recent MR  report59. Increased levels of alanine aminotransferases (ALT), the enzymes 
catalysing the conversion of alanine to pyruvate and glutamate, were already associated to T2DM, and could 
therefore underlie the observed causal effect.
Strengths and limitations. Our study has numerous strengths. First, is our use of two well characterized 
prospective cohorts (one for replication), whose participants have been followed longitudinally for more than 
10 years. This approach allowed us to investigate potential biomarkers in blood samples collected when individu-
als were still free of diabetes. Second, the robustness of our targeted methods and of our results is evidenced by 
the fact that we confirm many previous findings. Third, we triangulate evidence by combining these longitudinal 
association results with other causal inference techniques, such as MR.
The major limitation of this study is the relatively low number of incident diabetes cases that we could analyse, 
which prohibited us from new discoveries with unequivocal statistical evidence. In the light of these findings, 
we recommend future research focussing more on untargeted metabolomic approaches better exploring the vast 
space of metabolite species and the investigation of other omics biomarkers in parallel.
Another limitation concerns the MR analysis: pleiotropic effects of the chosen genetic instruments may lead 
to biased estimates. They may be underpowered because the metabolite GWASs were performed in only 7824 
individuals. In addition, the causal effect of metabolites without known QTLs cannot be investigated.
Conclusions. Our study has confirmed most of the identified-to-date metabolites in a medium-sized lon-
gitudinal population-based study (enriched for incident cases) and provided complementary evidence from 
bi-directional MR. However, the quest for early metabolic biomarkers predicting the development of T2DM 
requires more research effort including larger studies in order to understand the potentially minute contribu-
tions of many circulating metabolites.
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